- Home
- VYNE vs SER Comparison
VYNE vs SER Comparison
Compare VYNE & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYNE
- SER
- Stock Information
- Founded
- VYNE 2003
- SER 2017
- Country
- VYNE United States
- SER United States
- Employees
- VYNE N/A
- SER N/A
- Industry
- VYNE Biotechnology: Pharmaceutical Preparations
- SER Biotechnology: Pharmaceutical Preparations
- Sector
- VYNE Health Care
- SER Health Care
- Exchange
- VYNE Nasdaq
- SER Nasdaq
- Market Cap
- VYNE 41.9M
- SER 44.8M
- IPO Year
- VYNE 2018
- SER 2018
- Fundamental
- Price
- VYNE $2.32
- SER $4.78
- Analyst Decision
- VYNE Strong Buy
- SER
- Analyst Count
- VYNE 2
- SER 0
- Target Price
- VYNE $6.88
- SER N/A
- AVG Volume (30 Days)
- VYNE 129.4K
- SER 18.4K
- Earning Date
- VYNE 02-27-2025
- SER 11-12-2024
- Dividend Yield
- VYNE N/A
- SER N/A
- EPS Growth
- VYNE N/A
- SER N/A
- EPS
- VYNE N/A
- SER N/A
- Revenue
- VYNE $493,000.00
- SER $3,157,500.00
- Revenue This Year
- VYNE $28.30
- SER N/A
- Revenue Next Year
- VYNE N/A
- SER N/A
- P/E Ratio
- VYNE N/A
- SER N/A
- Revenue Growth
- VYNE 39.27
- SER 2454.55
- 52 Week Low
- VYNE $1.57
- SER $3.81
- 52 Week High
- VYNE $4.30
- SER $23.18
- Technical
- Relative Strength Index (RSI)
- VYNE 36.13
- SER 50.80
- Support Level
- VYNE $2.34
- SER $4.60
- Resistance Level
- VYNE $3.00
- SER $4.92
- Average True Range (ATR)
- VYNE 0.27
- SER 0.34
- MACD
- VYNE -0.08
- SER 0.02
- Stochastic Oscillator
- VYNE 8.24
- SER 38.75
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.